Immutrin
PrivateLast Round
Series A
Mar 24, 2026
Total Funding Raised
$87M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Immutrin is a biotechnology company that develops antibody therapies designed to deplete systemic amyloid deposits and reverse amyloidosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immutrin Comparables
Compare Immutrin with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Attralus | 80% | |
| AstraZeneca | 74% | |
| Prothena Corporation plc | 74% | |
Immutrin Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 24, 2026 |
Key People
Founding team and executive leadership
Immutrin Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cambridge Enterprise Ventures | Series A |
| Frazier Life Sciences | Series A |
| Cambridge Enterprise | Series A |
| Cambridge Innovation Capital | Series A |
| F-Prime Capital | Series A |
| Qiming Venture Partners | Series A |
| SR One | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 17, 2026
Grew 45% QoQ, from 11 to 16 employees.
- Jun 30, 2026
Grew 40% QoQ from 10 to 14 employees.
Immutrin Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Immutrin's valuation, stock price, and market status.